Bristol Myers Squibb receives USFDA accelerated approval of Krazati in combination with Cetuximab for CRC

Second FDA approval for KRAZATI - reinforcing its potential across tumor types

Jemperli trial continues to show positive results for deficient (dMMR) rectal cancer

Updated analysis from Memorial Sloan Kettering Cancer Center presented at ASCO 2024 has expanded to 42 patients with clinical complete response

Merck's oncology pipeline of DDRi and ADC poised to advance cancer treatment

Merck shared updates on the company’s oncology pipeline and focused R&D approach

Merck Specialities’ unique initiative to raise bladder cancer awareness

Takeda receives positive CHMP opinion for Fruquintinib in previously treated mCRC

If approved in the European Union, Fruquintinib will be the first novel targeted therapy for Metastatic Colorectal Cancer regardless of biomarker status in over a decade

Krazati monotherapy shows significant survival benefit in KRAS G12C-mutated NSCLC Phase III Krystal -12 data

The FDA assigned a Prescription Drug User Fee Act (PDUFA) goal date of June 21, 2024

Dr. Reddy's Laboratories launches Versavo in the UK

Versavo is the first Dr. Reddy's biosimilar product to be approved and launched in the UK

Eastman, SEG collaborate to launch INVU 10th anniversary collection with Tritan Renew

Tritan Renew, which is made with 50% certified recycled content derived from hard-to-recycle waste, performs like virgin-quality material

Clariant Healthcare debuts in CPhI India

Clariant Healthcare highlighted Vitipure Meglumine LEX and VitiPure Superior at the recently concluded CPhI India

Briefs: Atlas Life Sciences India and Vidhi Specialty Food Ingredients

Atlas Life Sciences (India) has successfully commenced the commercial production of API - Intermediate at its new plant at Chhatral,